At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Varenicline Attenuates Some of the Subjective and Physiological Effects of Intravenous Nicotine in Humans.
In Brief
A clinical study evaluating Varenicline, Placebo, and 1 other intervention for Smoking Cessation. Completed, enrolled 37 participants across 1 site.
Detailed Summary
To examine the effects of varenicline on the subjective, physiological and cognitive responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is approved as a treatment for smoking cessation. We predict that varenicline treatment will modify subjective, physiological and cognitive responses to IV nicotine.
Study Details
Timeline
Interventions
Varenicline (1 mg per day) given for 4 days prior to laboratory session
Sugar Pill
IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.